08:00 Fri 26 Jul 2019
Horizon Dis Grp plc - Block Listing Six Monthly Return
RNS
Block Listing Six Monthly Return and Block Listing Application
|
|
|
|
a) Horizon Discovery Limited Enterprise Management Incentive Share Option Scheme b) c) d) |
|
Period of return (from / to): |
From: |
To: |
Number of securities admitted and date of admission |
Total of 3,000,000 ordinary shares of 1p each, admission date a) 1,398,000 b) 1,392,000 c) 110,000 d) 100,000 Further 500,000 ordinary shares of 1p each, admission date a) 0 b) 150,000 c) 150,000 d) 200,000
|
|
Balance of unallotted securities under schemes from previous return: |
Total of 1,756,424 ordinary shares of 1p each, split a) 616,750 b) 926,020 c) 98,065 d) 115,589
|
|
Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for): |
0
|
|
Less: Number of securities issued/allotted under scheme(s) during period: |
Total of 32,432 ordinary shares of 1p each, split a) 7,000 b) 13,127 c) 12,305 d) 0 |
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
Total of 1,723,992 ordinary shares of 1p each, split a) 609,750 b) 912,893 c) 85,760 d) 115,589 |
ENDS
For further information from
Tel: +44 (0) 1223 655 580
Tel: +44 (0) 207 260 1000
Tel: +44 (0) 20 3709 5700
Email: horizon@consilium-comms.com
About
Built upon more than a decade of experience in the engineering of cell lines, Horizon offers an unmatched portfolio of tools and services to help scientists gain a greater understanding of gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.
Horizon's solutions enable almost any gene to be altered, or its function modulated, in human and other mammalian cell lines.
The Company's customers include many of the world's foremost academic institutes, global pharmaceutical and biotechnology companies as well as clinical diagnostic laboratories. Insight into the challenges faced by these organizations enables Horizon to focus efforts on development of innovative solutions that not only differentiate the Company's offering, but also fuel development of the next wave of precision medicines.
Horizon is headquartered in
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE